51
METHOD FOR REGULATING ALDEHYDE DEHYDROGENASE 1. July 27, 2017: US20170209403-A1

The present invention provides a method for regulating aldehyde dehydrogenase 1 (ALDH1) comprises administering all-trans retinoic acid to a subject. Further, the present invention also provides a method for treating solid malignancy comprises administering all-trans retinoic acid to a subject, prov ...


52
FUMARATE ESTER DOSAGE FORMS. August 17, 2017: US20170231942-A1

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One e ...


53
METHODS AND COMPOSITIONS FOR INHIBITING AND TREATING NEUROLOGICAL CONDITIONS. POPULATION BIO, September 7, 2017: US20170253930-A1

This document provides methods and materials related to treating subjects having specific genetic variations associated with neurological disorders such as Parkinson's disease.


54
BINDING DOMAINS DIRECTED AGAINST GPCR:G PROTEIN COMPLEXES AND USES DERIVED THEREOF. VIB VZW, Vrije Universiteit Brussel, The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of Michigan, September 7, 2017: US20170253644-A1

The present disclosure relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present disclosure relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encod ...


55
EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE. October 5, 2017: US20170281568-A1

The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol.


56
RANKL-SPECIFIC AGENT FOR TREATING METASTATIC DISEASE. Probiocon, November 9, 2017: US20170319687-A1

The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.


57
THERAPEUTIC AGENT FOR PAIN. ASTELLAS PHARMA, November 16, 2017: US20170327474-A1

[Problem] Provided is a pharmaceutical, in particular, a pharmaceutical composition which is useful for the treatment of pain. [Means for Solution] The present inventors have made extensive studies using model animals with pain for the purpose of providing a therapeutic agent for pain. As a result, ...


58
THERMORESPONSIVE CELL CULTURE SUPPORTS. November 30, 2017: US20170342375-A1

The present invention relates to a cell culture support comprising a substrate and a polymeric blend layer bound to the substrate. The polymeric blend layer comprises at least one thermoresponsive polymer and at least one coupling agent. The coupling agent is a non-protein coupling agent that has fu ...


59
DELIVERY SYSTEM FOR INFLATABLE IMPLANT. December 14, 2017: US20170354491-A1

An implant delivery system can be used to deliver an implant into a body. The implant delivery system can include an inflation tube and a tubular member surrounding the inflation tube. The inflation tube can be used to provide an inflation medium to the implant. The tubular member can have a distal ...


60
RECOMBINANT PHE-FREE PROTEINS FOR USE IN THE TREATMENT OF PHENYLKETONURIA. NEXTTOBE, January 18, 2018: US20180016613-A1

The present invention relates to a method for preparing a recombinant Phe-free or Phe-low protein, the method comprising using B. subtilis or B. licheniformis as an expression system and/or a recombinant host cell into which a nucleotide encoding a recombinant Phe-free or Phe-low protein has been in ...



Click the thumbnails below to visualize the patent trend.